Gene Therapy for Ventricular Tachyarrhythmias

About Rithim Biologics

Rithim Biologics is a private, preclinical-stage biotech developing a novel platform for cardiac arrhythmia treatment. The company's strategy integrates a proprietary surgical delivery catheter, the DAAViS™, with targeted gene therapies designed to prevent tachyarrhythmias. Led by a co-founding team with deep expertise in cardiac electrophysiology and medical device commercialization, the company has secured an NIH grant and its first US patent. Rithim operates in the high-potential but competitive fields of gene therapy and cardiac electrophysiology, targeting a significant unmet need for durable, non-ablative treatments.

Therapeutic Areas